Partnerships for organoid-based translational research & CRO integration

abc biopply is actively seeking strategic partnerships with Contract Research Organizations (CROs), biotechnology companies, and pharmaceutical partners to integrate advanced organoid-based systems into drug discovery and preclinical development workflows.

Our proprietary 3D CoSeedis™ multi-organoid platform enables human-relevant disease modeling and can complement existing in vitro and in vivo capabilities by providing deeper biological insight into therapeutic response, mechanism of action, and resistance.

We are particularly interested in collaborations that involve:

• integration of organoid models into CRO service portfolios

• joint translational research and discovery projects

• combination of organoid systems with in vivo, screening, imaging, or omics platforms

• early-stage validation to support decision-making before clinical development

Partnership models may include service-based collaboration, joint research projects, or longer-term strategic collaborations.

We aim to build long-term partnerships that enhance translational relevance, improve predictability, and accelerate the development of innovative therapeutics.